Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017...
August 04 2017 - 8:31AM
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
renal disease, today announced it will webcast its corporate
presentation at the Canaccord Genuity 37th Annual Growth Conference
in Boston on Wednesday, August 9, 2017 at 1:30 p.m. Eastern Time.
A live webcast of the presentation will be
accessible from Keryx’s website at http://investors.keryx.com
within the Investor Relations section under “webcasts and
presentations.” An archived version of the webcast will be
available for at least 15 days following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals,
Inc. Keryx Biopharmaceuticals, Inc., with headquarters in
Boston, Massachusetts, is a commercial stage company focused on
bringing innovative medicines to people with renal disease. Keryx
developed and commercializes Auryxia® (ferric citrate) in the U.S.
Ferric citrate is marketed as Riona® by Keryx’s Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In
September 2015, the European Commission granted European market
authorization for Fexeric® (ferric citrate coordination
complex). Keryx has programs underway to leverage its
development and commercial infrastructure, including potentially
expanding the indication of Auryxia and in-licensing medicines
for renal disease. For more information about Keryx, please
visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617-466-3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024